PECAM1 and neoplasm: In a 2015 study by Blank et al., high CD31 levels were associated with increased tumor angiogenesis and poor treatment response [44], indicating its relevance as a prognostic marker and its potential for evaluating treatment efficacy, especially in anti-angiogenic therapies.